M

MannKind Corp
D

MNKD

4.12000
USD
-0.11
(-2.49%)
مغلق
حجم التداول
45,179
الربح لكل سهم
0
العائد الربحي
-
P/E
41
حجم السوق
1,252,203,350
أصول ذات صلة
NEOUSD
NEOUSD
0.01739
(0.27%)
6.40755 USD
C
CYCC
-0.01000
(-0.69%)
1.44000 USD
E
EKSO
0.00400
(1.47%)
0.27590 USD
M
MNKD
-0.10500
(-2.49%)
4.12000 USD
N
NEO
0.13900
(1.91%)
7.41000 USD
P
PRTA
0.03000
(0.46%)
6.58000 USD
المزيد
الأخبار المقالات

العنوان: MannKind Corp

القطاع: Healthcare
الصناعة: Biotechnology
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.